

# Alan I So

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/700902/publications.pdf>

Version: 2024-02-01

34  
papers

1,103  
citations

471061

17  
h-index

395343

33  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1713  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world management of metastatic castration-resistant prostate cancer (mCRPC): A national multicenter cohort study.. Journal of Clinical Oncology, 2022, 40, 252-252.	0.8	1
2	Canadian consensus forum of key controversial areas in the management of advanced prostate cancer. Canadian Urological Association Journal, 2021, 15, 353-358.	0.3	2
3	Canadian Urological Association guideline: Management of small renal masses â€“ Full-text. Canadian Urological Association Journal, 2021, 16, E61-75.	0.3	10
4	Canadian Urological Association guideline: Management of small renal masses â€“ Summary of recommendations. Canadian Urological Association Journal, 2021, 16, 24-5.	0.3	1
5	Defining postoperative ileus and associated risk factors in patients undergoing radical cystectomy with an Enhanced Recovery After Surgery (ERAS) program. Canadian Urological Association Journal, 2020, 15, 33-39.	0.3	5
6	Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. Canadian Urological Association Journal, 2020, 15, E90-E96.	0.3	3
7	Metastatic Renal Cell Carcinoma to the Testis: A Clinicopathologic Analysis of Five Cases. Case Reports in Pathology, 2020, 2020, 1-6.	0.2	3
8	Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma. Scientific Reports, 2020, 10, 2026.	1.6	16
9	Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2020, 39, 33.	3.5	19
10	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 576.e11-576.e16.	0.8	3
11	A A Canadian consensus forum on the management of patients with advanced prostate cancer. Canadian Urological Association Journal, 2019, 14, E137-E149.	0.3	15
12	Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 721-726.	0.8	21
13	Inhibition of GLI2 with antisenseâ€“oligonucleotides: A potential therapy for the treatment of bladder cancer. Journal of Cellular Physiology, 2019, 234, 20634-20647.	2.0	10
14	Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. Canadian Urological Association Journal, 2019, 14, 17-23.	0.3	17
15	The impact of time to metastasis on overall survival in patients with prostate cancer. World Journal of Urology, 2018, 36, 1039-1046.	1.2	27
16	A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer. World Journal of Urology, 2018, 36, 215-220.	1.2	71
17	The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib. Oncotarget, 2018, 9, 22631-22641.	0.8	2
18	Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model. American Journal of Clinical and Experimental Urology, 2018, 6, 245-259.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study. <i>Prostate</i> , 2017, 77, 1356-1365.	1.2	7
20	Structured assessment and followup for patients with hereditary kidney tumour syndromes. <i>Canadian Urological Association Journal</i> , 2016, 10, 214.	0.3	12
21	Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML). <i>Urology</i> , 2016, 89, 19-26.	0.5	23
22	Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma. <i>Neoplasia</i> , 2015, 17, 805-816.	2.3	17
23	Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1024-1034.	1.9	27
24	Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance. <i>Journal of Clinical Oncology</i> , 2015, 33, 51-57.	0.8	268
25	Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: Results from a Canadian multicenter collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 441-448.	0.8	26
26	Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2402-2411.	1.9	38
27	GLI2 Knockdown Using an Antisense Oligonucleotide Induces Apoptosis and Chemosensitizes Cells to Paclitaxel in Androgen-Independent Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 5769-5777.	3.2	62
28	Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6944-6954.	3.2	71
29	The Role of Stress Proteins in Prostate Cancer. <i>Current Genomics</i> , 2007, 8, 252-261.	0.7	40
30	Antisense oligonucleotide therapy in the management of bladder cancer. <i>Current Opinion in Urology</i> , 2005, 15, 320-327.	0.9	15
31	Mechanisms of the development of androgen independence in prostate cancer. <i>World Journal of Urology</i> , 2005, 23, 1-9.	1.2	137
32	Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1837-1849.	1.9	83
33	Androgens and prostate cancer. <i>World Journal of Urology</i> , 2003, 21, 325-337.	1.2	40
34	Prostate specific antigen: an updated review. <i>Canadian Journal of Urology</i> , 2003, 10, 2040-50.	0.0	10